Evidence-Based Complementary and Alternative Medicine / 2020 / Article / Tab 4

Research Article

Assessment of the Efficacy and Safety of Ivy Leaf (Hedera helix) Cough Syrup Compared with Acetylcysteine in Adults and Children with Acute Bronchitis

Table 4

Relevant concomitant diseases and treatments.

Concomitant infections and other diseasesEA 575®ACCTotal value

No (N; %)66; 55.9%13; 61.9%79; 56.8%NS
Yes (N; %)54; 44.1%6; 38.1%60; 43.2%
Total118; 100.0%21; 100.0%139; 100.0%
Yes, namely
Bronchial asthma8; 6.8%0; 0%8; 5.8%NS
Otitis media4; 3.4%0; 0%4; 2.9%NS
Rhinosinusitis13; 11.0%2; 9.5%15; 10.8%NS
Other chronic respiratory diseases4; 3.4%1; 4.8%5; 3.6%NS
Allergies4; 3.4%0; 0%4; 2.9%NS
Inflammation of upper resp. tract21; 17.8%3; 14.3%24; 17.3%NS
EA 575®ACCTotal-value
Treatment of concomitant diseases
None (N; % of patient within treatment group)8; 6.8%0; 0.0%8; 5.8%NS
Antibiotic treatment22; 18.6%3; 14.3%25; 18.0%NS
Other treatment (N; %)23; 19.5%8; 38.1%31; 22.3%NS

Chi-squared test; NS = not significant (e.g., ); N = number of subjects.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.